Clinical Trial Update: Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the efficacy of gilteritinib in combination with the FLAI induction regimen for FLT3-mutated acute myeloid leukemia. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gilteritinib (gilteritinib)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Acute Myeloid Leukemia, FLT3 Gene Mutation | Phase 2 | Status: NOT_YET_RECRUITING